InvestorsHub Logo
Followers 466
Posts 26932
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 31

Friday, 09/07/2012 9:03:58 AM

Friday, September 07, 2012 9:03:58 AM

Post# of 62
September 7, 2012
07:14 EDT THRX, GSK Theravance recent weakness a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the recent weakness in shares of Theravance (THRX) as a buying opportunity as it believes Phase III data for Breo/Relvar and LAMA/LABA support regulatory approval and an eventual takeout by partner GlaxoSmithKline (GSK). Piper reiterates an Overweight rating on Theravance with a $35 price target.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent THRX News